Advertisement
Research Article

A Potent Class of GPR40 Full Agonists Engages the EnteroInsular Axis to Promote Glucose Control in Rodents

  • Jian Luo equal contributor,

    equal contributor Contributed equally to this work with: Jian Luo, Gayathri Swaminath

    Affiliation: Department of Metabolic Disorders, Amgen Inc., South San Francisco, California, United States of America

    X
  • Gayathri Swaminath equal contributor,

    equal contributor Contributed equally to this work with: Jian Luo, Gayathri Swaminath

    Affiliation: Department of Metabolic Disorders, Amgen Inc., South San Francisco, California, United States of America

    X
  • Sean P. Brown,

    Affiliation: Department of Therapeutic Discovery, Amgen Inc., South San Francisco, California, United States of America

    X
  • Jane Zhang,

    Affiliation: Department of Metabolic Disorders, Amgen Inc., South San Francisco, California, United States of America

    X
  • Qi Guo,

    Affiliation: Department of Metabolic Disorders, Amgen Inc., South San Francisco, California, United States of America

    X
  • Michael Chen,

    Affiliation: Department of Metabolic Disorders, Amgen Inc., South San Francisco, California, United States of America

    X
  • Kathy Nguyen,

    Affiliation: Department of Metabolic Disorders, Amgen Inc., South San Francisco, California, United States of America

    X
  • Thanhvien Tran,

    Affiliation: Department of Metabolic Disorders, Amgen Inc., South San Francisco, California, United States of America

    X
  • Lynn Miao,

    Affiliation: Department of Metabolic Disorders, Amgen Inc., South San Francisco, California, United States of America

    X
  • Paul J. Dransfield,

    Affiliation: Department of Therapeutic Discovery, Amgen Inc., South San Francisco, California, United States of America

    X
  • Marc Vimolratana,

    Affiliation: Department of Therapeutic Discovery, Amgen Inc., South San Francisco, California, United States of America

    X
  • Jonathan B. Houze,

    Affiliation: Department of Therapeutic Discovery, Amgen Inc., South San Francisco, California, United States of America

    X
  • Simon Wong,

    Affiliation: Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., South San Francisco, California, United States of America

    X
  • Maria Toteva,

    Affiliation: Department of Pharmaceutics, Amgen Inc., South San Francisco, California, United States of America

    X
  • Bei Shan,

    Affiliation: Department of Metabolic Disorders, Amgen Inc., South San Francisco, California, United States of America

    X
  • Frank Li,

    Affiliation: Department of Metabolic Disorders, Amgen Inc., South San Francisco, California, United States of America

    X
  • Run Zhuang,

    Affiliation: Department of Metabolic Disorders, Amgen Inc., South San Francisco, California, United States of America

    X
  • Daniel C.-H. Lin mail

    dclin@amgen.com

    Affiliation: Department of Metabolic Disorders, Amgen Inc., South San Francisco, California, United States of America

    X
  • Published: October 09, 2012
  • DOI: 10.1371/journal.pone.0046300

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.